Cargando…
Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
Myeloproliferative neoplasms are divided into essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Although ruxolitinib was proven to be effective in reducing symptoms, patients rarely achieve complete molecular remission. Therefore, it is relevant to identify new...
Autores principales: | Petiti, Jessica, Lo Iacono, Marco, Rosso, Valentina, Andreani, Giacomo, Jovanovski, Aleksandar, Podestà, Marina, Lame, Dorela, Gobbi, Marco De, Fava, Carmen, Saglio, Giuseppe, Frassoni, Francesco, Cilloni, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521327/ https://www.ncbi.nlm.nih.gov/pubmed/32790151 http://dx.doi.org/10.1111/jcmm.15730 |
Ejemplares similares
-
P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS
por: Petiti, J., et al.
Publicado: (2022) -
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms
por: Rosso, Valentina, et al.
Publicado: (2016) -
Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms
por: Petiti, Jessica, et al.
Publicado: (2022) -
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
por: Jovanovski, Aleksandar, et al.
Publicado: (2020) -
Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)